Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Crinetics Pharmaceuticals Inc
(NQ:
CRNX
)
54.47
+1.35 (+2.54%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Crinetics Pharmaceuticals Inc
< Previous
1
2
3
4
5
Next >
Crinetics to Highlight Broad Pipeline at ENDO 2023
June 09, 2023
Endocrine Society President to Present Crinetics CEO with John D. Baxter Prize for Entrepreneurship
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Where Crinetics Pharmaceuticals Stands With Analysts
June 08, 2023
Via
Benzinga
Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 04, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
The Latest Analyst Ratings for Crinetics Pharmaceuticals
April 24, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
March 30, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023
April 24, 2023
Via
Benzinga
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
February 28, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals's Return On Capital Employed Overview
December 26, 2022
Via
Benzinga
Crinetics' CRN04777 Shows Dose-Dependent Suppression of Fasting Insulin
March 31, 2022
Via
Benzinga
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 10, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
February 10, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference
January 09, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 12, 2022
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Provides Update on CRN04777 Program
November 28, 2022
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
November 22, 2022
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2022
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
October 13, 2022
Topline results for PATHFNDR-1 study expected in Q3 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2022
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism
October 06, 2022
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer
October 03, 2022
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals's Return On Capital Employed Overview
September 09, 2022
Benzinga Pro data, Crinetics Pharmaceuticals (NASDAQ:CRNX) reported Q2 sales of $439 thousand. Earnings fell to a loss of $42.38 million, resulting in a 22.38% decrease from last quarter.
Via
Benzinga
Crinetics Pharmaceuticals: Q2 Earnings Insights
August 12, 2022
Crinetics Pharmaceuticals (NASDAQ:CRNX) reported its Q2 earnings results on Friday, August 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Crinetics Pharmaceuticals Announces Positive Top-line Results From CRN04894 Early-Stage Trial
May 25, 2022
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) revealed positive topline results from a first-in-human Phase 1 clinical study of CRN04894 for the treatment of patients with Cushing's disease.
Via
Benzinga
The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine
May 25, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
88 Biggest Movers From Yesterday
May 26, 2022
Gainers The Very Good Food Company Inc. (NASDAQ: VGFC) shares jumped 118.2% to close at $0.2950 on Wednesday as the company announced it increased retail distribution across Canada with Loblaw...
Via
Benzinga
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
April 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal
Via
Benzinga
53 Biggest Movers From Yesterday
April 01, 2022
Gainers Longeveron Inc. (NASDAQ: LGVN) shares jumped 105.4% to close at $13.80 on Thursday after the company announced the publication of results from a Phase 1 trial testing...
Via
Benzinga
52 Biggest Movers From Yesterday
December 01, 2021
Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares climbed 128.6% to close at $5.03 on Tuesday. The FDA approved expanded labeling for Cumberland...
Via
Benzinga
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021
November 30, 2021
Upgrades Sidoti & Co. upgraded the previous rating for DMC Global Inc (NASDAQ:
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.